학술논문
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study
Document Type
Article
Author
Gaudinski, Martin R; Coates, Emily E; Novik, Laura; Widge, Alicia; Houser, Katherine V; Burch, Eugeania; Holman, LaSonji A; Gordon, Ingelise J; Chen, Grace L; Carter, Cristina; Nason, Martha; Sitar, Sandra; Yamshchikov, Galina; Berkowitz, Nina; Andrews, Charla; Vazquez, Sandra; Laurencot, Carolyn; Misasi, John; Arnold, Frank; Carlton, Kevin; Lawlor, Heather; Gall, Jason; Bailer, Robert T; McDermott, Adrian; Capparelli, Edmund; Koup, Richard A; Mascola, John R; Graham, Barney S; Sullivan, Nancy J; Ledgerwood, Julie E; Hendel, Cynthia Starr; Plummer, Sarah H.; Costner, Pamela; Saunders, Jamie; Mendoza, Floreliz; Eshun, Aba Mensima; Casazza, Joseph; Ola, Abidemi; Whalen, William; Wang, Xiaolin; Cunningham, Jennifer; Vasilenko, Olga; Boyd, Catina R.; Trofymenko, Olga; Burgos Florez, Maria Claudia; Hickman, Somia; Rothwell, Ro Shauna; Pittman, Iris R; Le, Lam Ngan; Larkin, Brenda D; Cox, Josephine H; Apte, Preeti J; Hicks, Renunda T; Trelles Cartagena, Cora; Williams, Pernell V; Requilman, LaShawn; Nguyen, Thuy; Tran, Colin; Vazquez, Sandra; Conan-Cibotti, Michelle; Stein, Judy; Beresnev, Tatiana
Source
The Lancet; March 2019, Vol. 393 Issue: 10174 p889-898, 10p
Subject
Language
ISSN
01406736; 1474547X
Abstract
mAb114 is a single monoclonal antibody that targets the receptor-binding domain of Ebola virus glycoprotein, which prevents mortality in rhesus macaques treated after lethal challenge with Zaire ebolavirus. Here we present expedited data from VRC 608, a phase 1 study to evaluate mAb114 safety, tolerability, pharmacokinetics, and immunogenicity.